决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Unraveling the immune evasion mechanisms in the tumor microenvironment of head and neck squamous cell carcinoma.
头颈部鳞状细胞癌(HNSCC)是一种高度侵袭性的恶性肿瘤,其特征是复杂的肿瘤微环境(TME),该微环境在肿瘤发生、进展和免疫逃逸中发挥关键作用。
头颈部鳞状细胞癌(HNSCC)是一种高度侵袭性恶性肿瘤,其复杂的肿瘤微环境(TME)在肿瘤发生、进展和免疫逃逸中发挥关键作用。近期进展揭示,免疫细胞浸润模式、免疫检查点失调与代谢重编程之间存在复杂相互作用,共同推动HNSCC免疫逃逸。尽管已有这些认识,仍存在重要挑战,包括对特定免疫逃逸通路了解不完整,以及缺乏个体化治疗策略。为弥补这些不足,本综述提出HNSCC免疫逃逸的全新“三位一体”调控网络,包括:(1)代谢重编程介导的免疫检查点调节;(2)基质细胞驱动的免疫功能障碍;(3)促进免疫耐受的表观遗传重塑。该框架为开发多靶点联合疗法提供理论基础,并提出克服免疫逃逸的新策略。此外,本文系统综述了目前对HNSCC微环境与免疫逃逸关系的认识,重点讨论PD-1/PD-L1抑制剂和CAR-T细胞治疗等新兴免疫疗法。借助先进的单细胞测序和空间转录组学技术,我们阐明HNSCC免疫景观的时空异质性,并提出“谱系可塑性驱动的免疫适应”新范式。这些见解不仅增进了对HNSCC生物学的理解,也为开发改善患者生存和生活质量的精准免疫疗法铺平道路。通过整合多学科视角,本文强调靶向TME对于实现持久临床缓解及克服免疫治疗耐药的重要性。
Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive malignancy characterized by a complex tumor microenvironment (TME) that plays a pivotal role in tumor initiation, progression, and immune evasion. Recent advancements have highlighted the intricate interplay between immune cell infiltration patterns, immune checkpoint dysregulation, and metabolic reprogramming in driving HNSCC immune escape. Despite these insights, significant challenges remain, including the incomplete understanding of specific immune evasion pathways and the lack of personalized therapeutic strategies. To address these gaps, this review introduces a novel "Trinity" regulatory network of immune evasion in HNSCC, encompassing: (1) metabolic reprogramming-mediated immune checkpoint modulation, (2) stromal cell-driven immune dysfunction, and (3) epigenetic remodeling fostering immune tolerance. This framework provides a theoretical foundation for the development of multi-targeted combination therapies and offers innovative strategies to overcome immune evasion. Additionally, this review systematically synthesizes the current understanding of the relationship between the HNSCC microenvironment and immune escape, with a focus on emerging immunotherapeutic approaches such as PD-1/PD-L1 inhibitors and CAR-T cell therapy. Leveraging cutting-edge single-cell sequencing and spatial transcriptomics, we elucidate the spatiotemporal heterogeneity of the HNSCC immune landscape and propose a new paradigm of "lineage plasticity-driven immune adaptation." These insights not only advance our understanding of HNSCC biology but also pave the way for the development of precision immunotherapies aimed at improving patient survival and quality of life. By integrating multidisciplinary perspectives, this work underscores the importance of targeting the TME to achieve durable clinical responses and overcome immunotherapy resistance in HNSCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。